Cargando…

Recent advances in managing systemic sclerosis

How the main components in systemic sclerosis—namely autoimmunity, vasculopathy, and fibrosis—fit together is still not sufficiently clear. However, vascular treatment options are well established, the body of evidence for the efficacy of immunomodulatory approaches is increasing, and now at least o...

Descripción completa

Detalles Bibliográficos
Autores principales: Aringer, Martin, Erler, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288672/
https://www.ncbi.nlm.nih.gov/pubmed/28184295
http://dx.doi.org/10.12688/f1000research.10022.1
_version_ 1782504372057407488
author Aringer, Martin
Erler, Anne
author_facet Aringer, Martin
Erler, Anne
author_sort Aringer, Martin
collection PubMed
description How the main components in systemic sclerosis—namely autoimmunity, vasculopathy, and fibrosis—fit together is still not sufficiently clear. However, vascular treatment options are well established, the body of evidence for the efficacy of immunomodulatory approaches is increasing, and now at least one hopeful substance that may directly interfere with fibrosis is being tested. Although we still wait for important breakthroughs, there is grounds for hope that better therapeutic options will be available in the near future.
format Online
Article
Text
id pubmed-5288672
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-52886722017-02-08 Recent advances in managing systemic sclerosis Aringer, Martin Erler, Anne F1000Res Review How the main components in systemic sclerosis—namely autoimmunity, vasculopathy, and fibrosis—fit together is still not sufficiently clear. However, vascular treatment options are well established, the body of evidence for the efficacy of immunomodulatory approaches is increasing, and now at least one hopeful substance that may directly interfere with fibrosis is being tested. Although we still wait for important breakthroughs, there is grounds for hope that better therapeutic options will be available in the near future. F1000Research 2017-01-30 /pmc/articles/PMC5288672/ /pubmed/28184295 http://dx.doi.org/10.12688/f1000research.10022.1 Text en Copyright: © 2017 Aringer M and Erler A http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Aringer, Martin
Erler, Anne
Recent advances in managing systemic sclerosis
title Recent advances in managing systemic sclerosis
title_full Recent advances in managing systemic sclerosis
title_fullStr Recent advances in managing systemic sclerosis
title_full_unstemmed Recent advances in managing systemic sclerosis
title_short Recent advances in managing systemic sclerosis
title_sort recent advances in managing systemic sclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288672/
https://www.ncbi.nlm.nih.gov/pubmed/28184295
http://dx.doi.org/10.12688/f1000research.10022.1
work_keys_str_mv AT aringermartin recentadvancesinmanagingsystemicsclerosis
AT erleranne recentadvancesinmanagingsystemicsclerosis